Wildy logo
(020) 7242 5778

Wildy’s Book News

Book News cover photo

Vol 21 No 9 Sept/Oct 2016

Book of the Month

Cover of Goode on Commercial Law

Goode on Commercial Law

Edited by: Ewan McKendrick
Price: £170.00

Pupillage & Student Offers

Special Discounts for Pupils, Newly Called & Students

Read More ...

Secondhand & Out of Print

Browse Secondhand Online


The Ethics of Personalised Medicine: Critical Perspectives

Image not available lge
Edited by: Jan Schildmann, Sebastian Wascher, Verena Sandow, Jochen Vollmann

ISBN13: 9781472447968
Published: May 2015
Publisher: Ashgate Publishing Ltd
Country of Publication: UK
Format: Hardback
Price: £70.00

Despatched in 6 to 8 days.

In recent times, the phrase a "personalised medicine has become the symbol of medical progress and a label for better health care in the future. However, a controversial debate has developed around whether these promises of better, more personal and more cost-efficient medicine are realistic. This book brings together leading researchers from across Europe and North America, from both normative and empirical disciplines, who take a more critical view of the often encountered hype associated with personalised medicine.

Partially drawing on a four year collaborative research project funded by the German Ministry for Education and Research, the book presents a multidisciplinary debate on the current state of research on the ethical, legal and social implications of personalised medicine. At a time when future health care is a topic of much discussion, this book provides valuable policy recommendations for the way forward. This study will be of interest to researchers from various disciplines including philosophy, bioethics, law and social sciences.

Image not available lge
Medical Law
Introduction, Jochen Vollmann, Verena Sandow, Sebastian Wascher and Jan Schildmann
Part I: Personalised Medicine
Medicine for the Person? Concepts and Contextual Aspects: What is personalised medicine? Sharpening a vague term based on a systematic literature review, Sebastian Schleidgen, Corinna Klingler, Teresa Bertram, Wolf H. Rogowski and Georg Marckmann
Alarming symptoms of a paradigm shift? An approach to bridge the gap between hypothetical ethics and the current status of individualised medicine research, Tobias Fischer, Marcus Dorr, Robin Haring and Martin Langanke
Personalised medicine: getting past the controversies, George P. Browman
Patient as person in personalised medicine: autonomy, responsibility and the body, Thomas Wabel
The authority of corporeality and emotions: the new phenomenology and its relevance to the German debate on personalised medicine, Mathias Wirth
Towards integration of 'personalised' and 'person-centred' medicine: the concept of 'integrative and personalised health care', Peter Heusser
Part II: Personalised Medicine in Clinical and Practical Research
Ethical considerations for developing a best-practice guideline for next generation sequencing in oncology, Eva C. Winkler, Klaus Tanner, Hanno Glimm and Christof von Kalle
Practice variation across consent templates for biobank research: a survey of German biobanks, Irene Hirschberg, Hannes Kahrass and Daniel Strech
Individualised medicine in the diagnosis and prognosis of patients younger than 65 years with normal karyotype acute myeloid leukemia: a systematic review and meta-analysis of the impact of Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD), Matthias Port, Miriam Bottcher, Felicitas Thol, Nicole Trachte, Jurgen Wasem, Arnold Ganser, Laura Pouryamout and Anja Neumann
Taking it personally: patients' perspectives on personalised medicine and its ethical relevance, Sabine Wohlke, Julia Perry and Silke Schicktanz
'Personalised medicine' in oncology: physicians' perspectives on contributions to and challenges for clinical practice, Sebastian Wascher, Jan Schildmann, Caroline Brall and Jochen Vollmann
Through thick and big: data-rich medicine in the era of personalisation, Barbara Prainsack
Part III Personalised Medicine in Health-Care Systems
Benefit assessment of personalised interventions: methodological challenges and approaches to a solution, Jurgen Windeler and Stefan Lange
The relevance of the analytic validity of genetic biomarker tests in personalised medicine in oncology, Franz Hessel
Approval and reimbursement of personalised drugs: interim results of the adjustment process, Michael Noweski, Anke Walendzik, Franz Hessel, Rebecca Jahn and Jurgen Wasem
Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?, Wolf H. Rogowski, Scott D. Grosse, Jorg Schmidtke and Georg Marckmann
Personalised medicine as orphan drugs? Legal and ethical questions, Sina Gottwald and Stefan Huster
Personalised medicine: priority setting and opportunity costs in European public health-care systems, Jochen Vollmann
Part IV Personalised Medicine in Oncology
Recommendations for Future Development: 'Personalised medicine': multidisciplinary perspectives and interdisciplinary recommendations on a framework for future research and practice, Jan Schildmann, Miriam Bottcher, Maria Gabriel, Arnold Ganser, Sina Gottwald, Franz Hessel, Stefan Huster, Rebecca Jahn, Anja Neumann, Michael Noweski, Matthias Port, Laura Pouryamout, Verena Sandow, Felicitas Thol, Sebastian Wascher, Anke Walendzik, Jurgen Wasem and Jochen Vollmann